Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 9/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5349695 | 0.99 | ACP1 (0.43) | ACP1AVPR1AADORA2ASMN1; SMN2KDM1A | |
| SCHEMBL4822245 | 0.81 | ACP1 (0.47) | ACP1 | |
| SCHEMBL4823939 | 0.81 | KMT2A (0.49) | ACP1AVPR1AADORA2A | |
| SCHEMBL4821618 | 0.81 | ACP1 (0.47) | ACP1ADORA2ASMN1; SMN2 | |
| SCHEMBL4821056 | 0.76 | NPBWR1 (0.51) | ACP1SMN1; SMN2 | |
| SCHEMBL4826125 | 0.68 | MAP4K4 (0.43) | ACP1 | |
| SCHEMBL20923954 | 0.67 | KDM1A (0.68) | KDM1AMAOB | |
| SCHEMBL15661355 | 0.67 | PDE4D (0.45) | ACP1KDM1AMAOBPFKFB3 | |
| SCHEMBL4820817 | 0.67 | ACP1 (0.43) | ACP1ADORA2ASMN1; SMN2 | |
| SCHEMBL4824439 | 0.66 | ADORA2A (0.54) | ACP1ADORA2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-7189714-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20040077644-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| EP-1339688-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036567-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077644-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | ACP1 2295/4885AVPR1A 412/4885ADORA2A 471/4885 |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | ACP1 2923/4885AVPR1A 259/4885ADORA2A 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.